- Home
- SONN
as 07-01-2024 4:00pm EST
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 5.1M | IPO Year: | N/A |
| Target Price: | $47.85 | AVG Volume (30 days): | 61.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.87 - $12.10 | Next Earning Date: | 08-12-2024 |
| Revenue: | $92,731 | Revenue Growth: | -53.29% |
| Revenue Growth (this year): | -54.45% | Revenue Growth (next year): | N/A |
Latest Sonnet BioTherapeutics Holdings Inc. News
SONN Breaking Stock News: Dive into SONN Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
GlobeNewswire
19 days ago
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
GlobeNewswire
a month ago
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
ACCESSWIRE
a month ago
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
ACCESSWIRE
a month ago
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
ACCESSWIRE
2 months ago
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
ACCESSWIRE
2 months ago
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
Newsfile
2 months ago
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
Share on Social Networks:
Disclaimer
The information presented on this page, "SONN Sonnet BioTherapeutics Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.